Paper39007759
Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.
Hong CR and 11 others. J Med Chem, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers. Papers, record 39007759. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39007759
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA-Activated Protein Kinase | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Radiation-Sensitizing Agents | Major topic |
| Humans | |
| Animals | |
| Structure-Activity Relationship | |
| Mice | |
| Cell Line, Tumor | |
| Imidazoles | |
| Pyridones | |
| Xenograft Model Antitumor Assays | |
| Mice, Nude | |
| Rats |
Source PubMed
References74
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35978693 | Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK. | ACS Med Chem Lett | 2022 | https://conductscience.org/library/papers/35978693 | PubMed |
| 2 | 9510041 | A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. | Radiother Oncol | 1998 | https://conductscience.org/library/papers/9510041 | PubMed |
| 3 | 38426642 | Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models. | Mol Oncol | 2024 | https://conductscience.org/library/papers/38426642 | PubMed |
| 4 | 18849971 | Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. | Nat Chem Biol | 2008 | https://conductscience.org/library/papers/18849971 | PubMed |
| 5 | 33077952 | Dimers of DNA-PK create a stage for DNA double-strand break repair. | Nat Struct Mol Biol | 2021 | https://conductscience.org/library/papers/33077952 | PubMed |
| 6 | 19925430 | 3D-QSAR studies on a series of inhibitors docked into a new homology model of the DNA-PK receptor. | Curr Pharm Des | 2009 | https://conductscience.org/library/papers/19925430 | PubMed |
| 7 | 31490091 | Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. | Int J Radiat Biol | 2019 | https://conductscience.org/library/papers/31490091 | PubMed |
| 8 | 21606941 | Targeting hypoxia in cancer therapy. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21606941 | PubMed |
| 9 | 28652322 | Cryo-EM structure of the DNA-PK holoenzyme. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28652322 | PubMed |
| 10 | 32220971 | Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/32220971 | PubMed |
| 11 | 23636326 | mTOR kinase structure, mechanism and regulation. | Nature | 2013 | https://conductscience.org/library/papers/23636326 | PubMed |
| 12 | 36471053 | Targeting DNA damage response pathways in cancer. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/36471053 | PubMed |
| 13 | 2215662 | The scid mutation in mice causes a general defect in DNA repair. | Nature | 1990 | https://conductscience.org/library/papers/2215662 | PubMed |
| 14 | 31541630 | Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. | Biochem Pharmacol | 2019 | https://conductscience.org/library/papers/31541630 | PubMed |
| 15 | 21664823 | Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines. | Bioorg Med Chem | 2011 | https://conductscience.org/library/papers/21664823 | PubMed |
| 16 | 19133841 | Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. | Biochem J | 2009 | https://conductscience.org/library/papers/19133841 | PubMed |
| 17 | 34428039 | BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. | J Med Chem | 2021 | https://conductscience.org/library/papers/34428039 | PubMed |
| 18 | 37298933 | Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers. | Molecules | 2023 | https://conductscience.org/library/papers/37298933 | PubMed |
| 19 | 23386830 | Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. | Front Pharmacol | 2013 | https://conductscience.org/library/papers/23386830 | PubMed |
| 20 | 37351169 | DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo. | Theranostics | 2023 | https://conductscience.org/library/papers/37351169 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42266865 | Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation. | RSC Med Chem | 2026 | https://conductscience.org/library/papers/42266865 | PubMed |
| 41427993 | Multi-scale in-silico modelling to unveil structural requirements for DNA-PK inhibitors as radiosensitizers and MolSHAP based design of novel ligands. | J Comput Aided Mol Des | 2025 | https://conductscience.org/library/papers/41427993 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| PIK3CD | 5293 | PubTator's text mining | https://conductscience.org/library/genes/5293 | NCBI Gene |
| PRKDC | 5591 | PubTator's text mining | https://conductscience.org/library/genes/5591 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39007759
GET https://conductscience.org/api/papers/v1/39007759/references?page=2